Targeted Inhibition of BRAF Kinase: Opportunities and Challenges for Therapeutics in Melanoma

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2011 Oct 11

PMID 21981139

Citations 10

Authors

Rolando Perez-Lorenzo

Bin Zheng

Affiliations

Soon will be listed here.

Abstract

Malignant melanoma is the most aggressive form of skin cancer and its incidence has increased dramatically in the last two decades. Even with a high rate of success in the treatment of early stages of this malignancy, currently there are no effective strategies for the treatment of advanced metastatic melanoma. Much effort has been put into the use of different target-specific drugs, among which BRAF kinase-specific small-molecule inhibitors have rendered promising results as therapeutic agents in metastatic melanoma. Nonetheless, some side effects, such as development of SCC (squamous cell carcinoma), as well as tumour resistance and recurrence, are common limitations of this therapeutic strategy. The use of combination treatments in which different regulatory pathways or the immunological response are targeted seems to be a promising tool for the future success of melanoma therapeutics.

Citing Articles

BRAF Inhibition and UVB Light Synergistically Promote Papillomavirus 1-Induced Skin Tumorigenesis.

Dorfer S, Ressler J, Riebenbauer K, Kancz S, Purkhauser K, Bachmayr V Cancers (Basel). 2024; 16(18).

PMID: 39335105 PMC: 11440113. DOI: 10.3390/cancers16183133.

Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells.

Tchelougou D, Malaquin N, B Cardin G, Desmul J, Turcotte S, Rodier F Front Cell Dev Biol. 2024; 12:1368711.

PMID: 38946802 PMC: 11211604. DOI: 10.3389/fcell.2024.1368711.

Inducible Mouse Models for Cancer Drug Target Validation.

Jeong J J Cancer Prev. 2017; 21(4):243-248.

PMID: 28053958 PMC: 5207608. DOI: 10.15430/JCP.2016.21.4.243.

Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness.

Jobe N, Rosel D, Dvorankova B, Kodet O, Lacina L, Mateu R Histochem Cell Biol. 2016; 146(2):205-17.

PMID: 27102177 DOI: 10.1007/s00418-016-1433-8.

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.

Fofaria N, Frederick D, Sullivan R, Flaherty K, Srivastava S Oncotarget. 2015; 6(38):40535-56.

PMID: 26497853 PMC: 4747351. DOI: 10.18632/oncotarget.5755.

References

Siskind V, Hughes M, Palmer J, Symmons J, Aitken J, Martin N . Nevi, family history, and fair skin increase the risk of second primary melanoma. J Invest Dermatol. 2010; 131(2):461-7. PMC: 3045696. DOI: 10.1038/jid.2010.298. View

Smalley K, Lioni M, Palma M, Xiao M, Desai B, Egyhazi S . Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008; 7(9):2876-83. PMC: 2651569. DOI: 10.1158/1535-7163.MCT-08-0431. View

Hansen J, Grina J, Newhouse B, Welch M, Topalov G, Littman N . Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2008; 18(16):4692-5. DOI: 10.1016/j.bmcl.2008.07.002. View

Pratilas C, Solit D . Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res. 2010; 16(13):3329-34. PMC: 2912210. DOI: 10.1158/1078-0432.CCR-09-3064. View

Robert C, Arnault J, Mateus C . RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2010; 23(2):177-82. DOI: 10.1097/CCO.0b013e3283436e8c. View

Willmore-Payne C, Holden J, Tripp S, Layfield L . Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol. 2005; 36(5):486-93. DOI: 10.1016/j.humpath.2005.03.015. View

Montagut C, Sharma S, Shioda T, McDermott U, Ulman M, Ulkus L . Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008; 68(12):4853-61. PMC: 2692356. DOI: 10.1158/0008-5472.CAN-07-6787. View

Arkenau H, Kefford R, Long G . Targeting BRAF for patients with melanoma. Br J Cancer. 2010; 104(3):392-8. PMC: 3049553. DOI: 10.1038/sj.bjc.6606030. View

Solit D, Sawyers C . Drug discovery: How melanomas bypass new therapy. Nature. 2010; 468(7326):902-3. DOI: 10.1038/468902a. View

10.

Zhang C, Bollag G . Scaffold-based design of kinase inhibitors for cancer therapy. Curr Opin Genet Dev. 2009; 20(1):79-86. DOI: 10.1016/j.gde.2009.10.010. View

11.

Liang S, Sharma A, Peng H, Robertson G, Dong C . Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res. 2007; 67(12):5814-20. PMC: 2724629. DOI: 10.1158/0008-5472.CAN-06-4233. View

12.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

13.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

14.

Warmka J, Mauro L, Wattenberg E . Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras. J Biol Chem. 2004; 279(32):33085-92. DOI: 10.1074/jbc.M403120200. View

15.

Bourcier C, Jacquel A, Hess J, Peyrottes I, Angel P, Hofman P . p44 mitogen-activated protein kinase (extracellular signal-regulated kinase 1)-dependent signaling contributes to epithelial skin carcinogenesis. Cancer Res. 2006; 66(5):2700-7. DOI: 10.1158/0008-5472.CAN-05-3129. View

16.

Joseph E, Pratilas C, Poulikakos P, Tadi M, Wang W, Taylor B . The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A. 2010; 107(33):14903-8. PMC: 2930420. DOI: 10.1073/pnas.1008990107. View

17.

Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S . PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 2010; 23(2):190-200. PMC: 2848976. DOI: 10.1111/j.1755-148X.2010.00685.x. View

18.

Nazarian R, Shi H, Wang Q, Kong X, Koya R, Lee H . Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326):973-7. PMC: 3143360. DOI: 10.1038/nature09626. View

19.

Shao Y, Aplin A . Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 2010; 70(16):6670-81. PMC: 2922482. DOI: 10.1158/0008-5472.CAN-09-4471. View

20.

Wellbrock C, Karasarides M, Marais R . The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004; 5(11):875-85. DOI: 10.1038/nrm1498. View